p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. 1995

M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
Department of Pharmacology and Toxicology, University of Oulu, Finland.

p53 inhibits cell cycle progression and DNA damaging cytostatics induce p53 protein expression, indicating that p53 responds to DNA damage. We have measured benzo[a]pyrene (BP)-induced DNA damage in association with p53 expression. The most relevant DNA adducts for carcinogenesis, benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts, were measured by synchronous fluorescence spectrophotometry and p53 immunohistochemistry using polyclonal antibody CM1, which detects both wild-type and mutated forms of p53. Activation of BP in A-549 lung carcinoma and MCF-7 breast adenocarcinoma cell lines containing wild-type p53 was followed by an increase in p53 protein expression. alpha-Naphthoflavone, an inhibitor of cytochrome P450 (CYP)1A1, decreased both the formation of diolepoxide metabolites and the p53 response. The cell lines not able to activate BP, A-427 and SK-LU-1 (both human lung carcinomas), SK-MES-1 (human lung squamous carcinoma) and human fibroblasts, did not show any increase in p53 immunohistochemistry. The OVCAR-3 ovarian adenocarcinoma cell line, containing a mutation in exon 7 of p53, and the SK-LU-1 cell line expressed very high levels of p53 protein before BP treatment and no increase in p53 immunohistochemistry was seen. These findings indicate that p53 protein is part of the response of the cells to BP-induced DNA damage.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002274 Carcinogens, Environmental Carcinogenic substances that are found in the environment. Environmental Carcinogens
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005260 Female Females
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
April 1994, Carcinogenesis,
M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
December 1992, Carcinogenesis,
M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
January 2011, Methods in molecular biology (Clifton, N.J.),
M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
January 1991, Progress in clinical and biological research,
M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
September 1999, Carcinogenesis,
M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
July 1995, Carcinogenesis,
M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
June 1996, Carcinogenesis,
M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
September 1992, Analytical biochemistry,
M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
June 2004, Chemical research in toxicology,
M Rämet, and K Castrén, and K Järvinen, and K Pekkala, and T Turpeenniemi-Hujanen, and Y Soini, and P Pääkkö, and K Vähäkangas
January 1999, Mutation research,
Copied contents to your clipboard!